BR9507046A - Composto prodroga de um composto originário compusiçao farmacêutica processos para antagonizar o efeito de substância p em seu sitio receptor ou para bloquear receptores de neuroquinina- 1 em um mamifero para tratar ou prevenir dor ou nocicepçao atribuivel a ou associada com enxaqueca uma condiçao selecionada no grupo consistindo de neuropatia diabética periférica relacionada com aids induzida por quimioterapia e neuralgia asma emese e artrite para tratar fibrose cistica e processo para preparar - Google Patents

Composto prodroga de um composto originário compusiçao farmacêutica processos para antagonizar o efeito de substância p em seu sitio receptor ou para bloquear receptores de neuroquinina- 1 em um mamifero para tratar ou prevenir dor ou nocicepçao atribuivel a ou associada com enxaqueca uma condiçao selecionada no grupo consistindo de neuropatia diabética periférica relacionada com aids induzida por quimioterapia e neuralgia asma emese e artrite para tratar fibrose cistica e processo para preparar

Info

Publication number
BR9507046A
BR9507046A BR9507046A BR9507046A BR9507046A BR 9507046 A BR9507046 A BR 9507046A BR 9507046 A BR9507046 A BR 9507046A BR 9507046 A BR9507046 A BR 9507046A BR 9507046 A BR9507046 A BR 9507046A
Authority
BR
Brazil
Prior art keywords
treat
compound
emesis
migraine
asthma
Prior art date
Application number
BR9507046A
Other languages
English (en)
Inventor
Conrad P Dorn
Jeffrey J Hale
Malcolm Maccoss
Sander G Mills
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22767887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9507046(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9507046A publication Critical patent/BR9507046A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R16/00—Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for
    • B60R16/02—Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric constitutive elements
    • B60R16/037—Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric constitutive elements for occupant comfort, e.g. for automatic adjustment of appliances according to personal settings, e.g. seats, mirrors, steering wheel
    • B60R16/0373—Voice control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9507046A 1994-03-04 1995-02-28 Composto prodroga de um composto originário compusiçao farmacêutica processos para antagonizar o efeito de substância p em seu sitio receptor ou para bloquear receptores de neuroquinina- 1 em um mamifero para tratar ou prevenir dor ou nocicepçao atribuivel a ou associada com enxaqueca uma condiçao selecionada no grupo consistindo de neuropatia diabética periférica relacionada com aids induzida por quimioterapia e neuralgia asma emese e artrite para tratar fibrose cistica e processo para preparar BR9507046A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20677194A 1994-03-04 1994-03-04
PCT/US1995/002551 WO1995023798A1 (en) 1994-03-04 1995-02-28 Prodrugs of morpholine tachykinin receptor antagonists

Publications (1)

Publication Number Publication Date
BR9507046A true BR9507046A (pt) 1997-09-09

Family

ID=22767887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507046A BR9507046A (pt) 1994-03-04 1995-02-28 Composto prodroga de um composto originário compusiçao farmacêutica processos para antagonizar o efeito de substância p em seu sitio receptor ou para bloquear receptores de neuroquinina- 1 em um mamifero para tratar ou prevenir dor ou nocicepçao atribuivel a ou associada com enxaqueca uma condiçao selecionada no grupo consistindo de neuropatia diabética periférica relacionada com aids induzida por quimioterapia e neuralgia asma emese e artrite para tratar fibrose cistica e processo para preparar

Country Status (30)

Country Link
US (4) US5716942A (pt)
EP (1) EP0748320B1 (pt)
JP (1) JP3073770B2 (pt)
KR (1) KR977001713A (pt)
CN (1) CN1075812C (pt)
AT (1) ATE227722T1 (pt)
AU (1) AU700611B2 (pt)
BG (1) BG62811B1 (pt)
BR (1) BR9507046A (pt)
CA (1) CA2183250C (pt)
CO (1) CO4340689A1 (pt)
CZ (1) CZ288241B6 (pt)
DE (2) DE69528823T2 (pt)
ES (1) ES2184794T3 (pt)
FI (1) FI963450A0 (pt)
FR (1) FR08C0019I2 (pt)
HR (1) HRP950099A2 (pt)
HU (1) HUT76324A (pt)
IL (1) IL112778A0 (pt)
LV (1) LV11688B (pt)
MX (1) MX9603845A (pt)
NO (1) NO310074B1 (pt)
NZ (1) NZ282586A (pt)
PL (1) PL180522B1 (pt)
RU (1) RU2170233C2 (pt)
SK (1) SK112396A3 (pt)
TW (1) TW385308B (pt)
WO (1) WO1995023798A1 (pt)
YU (1) YU14495A (pt)
ZA (1) ZA951780B (pt)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
BR9408442A (pt) * 1993-12-29 1997-08-05 Merck Sharp & Dohme Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
WO1995030674A1 (en) * 1994-05-05 1995-11-16 Merck Sharp & Dohme Limited Morpholine derivatives and their use as antagonists of tachikinins
GB9505491D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9523244D0 (en) * 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
ATE293975T1 (de) * 1996-12-02 2005-05-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6613765B1 (en) * 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
EP0942728A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating sexual dysfunction
CA2273809A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating movement disorders
WO1998024443A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
GB9813025D0 (en) * 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
DK1157005T3 (da) 1999-02-24 2005-02-14 Hoffmann La Roche 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
TR200102490T2 (tr) 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil türevleri
ATE496032T1 (de) 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6552025B1 (en) * 1999-11-24 2003-04-22 Emory University Diimino-piperazine derivatives for use as modulators of cell regulation
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
RS50932B (sr) 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
MY130373A (en) * 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) * 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
AR039625A1 (es) * 2002-04-18 2005-03-02 Merck & Co Inc Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
ATE366576T1 (de) 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
NZ544244A (en) 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
WO2005033079A1 (ja) * 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
NZ548225A (en) 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2246687B2 (es) 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
RU2006141358A (ru) 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JPWO2006016548A1 (ja) * 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
CA2576530A1 (en) * 2004-08-11 2006-02-23 Donald L. Barbeau Noncardiotoxic pharmaceutical compounds
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
AR051475A1 (es) * 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
CA2601935C (en) 2005-02-22 2013-04-09 F. Hoffmann-La Roche Ag Nk1 antagonists
PL1863767T3 (pl) 2005-03-23 2009-08-31 Helsinn Healthcare Sa Metabolity antagonistów NK-1 do leczenia wymiotów
WO2006106711A1 (ja) * 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
DK1928427T3 (da) 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US8080656B2 (en) * 2005-10-05 2011-12-20 Ranbaxy Laboratories Limited Process for the preparation of aprepitant
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US9227958B2 (en) * 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8183264B2 (en) * 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
BRPI0810402A2 (pt) 2007-04-20 2014-11-04 Hoffmann La Roche Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3
CN102702185A (zh) * 2007-04-27 2012-10-03 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐的结晶
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR101167774B1 (ko) 2007-08-07 2012-07-24 에프. 호프만-라 로슈 아게 Ｎｋ3 수용체 길항제로서의 피롤리딘 아릴-에터
US20090076008A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched fosaprepitant
US20090076007A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched aprepitant
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
ES2550003T5 (es) * 2008-07-17 2018-08-22 Glenmark Pharmaceuticals Limited Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR20110136813A (ko) 2009-03-17 2011-12-21 다이이찌 산쿄 가부시키가이샤 아미드 유도체
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
AR077328A1 (es) 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011045817A2 (en) * 2009-10-15 2011-04-21 Sandoz Private Limited Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
US20130245253A1 (en) * 2010-03-26 2013-09-19 Department Of Veterans Affairs Conjugated Neuroactive Steroid Compositions And Methods Of Use
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
MY150939A (en) 2010-07-13 2014-03-14 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
MX336966B (es) 2011-01-13 2016-02-08 Novartis Ag Novedosos derivados y su uso en el tratamiento de transtornos neurologicos.
CN102127031B (zh) * 2011-01-17 2012-10-17 江苏江神药物化学有限公司 一种麻黄碱类化合物季胺盐及其合成方法和应用
US9067924B2 (en) * 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
IN2013MN02170A (pt) 2011-04-21 2015-06-12 Piramal Entpr Ltd
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
US9073909B2 (en) * 2011-06-07 2015-07-07 Hoffmann-La Roche Inc. [1,3]oxazines
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
CN102977142B (zh) * 2011-09-02 2017-03-29 江苏豪森药业集团有限公司 福沙匹坦二甲葡胺的制备方法
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2837381A4 (en) 2011-12-13 2015-12-09 Servicio Andaluz De Salud USE OF AGENTS MODIFYING THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2013168176A2 (en) * 2012-03-30 2013-11-14 Glenmark Generics Limited Process for preparation of fosaprepitant and salt thereof
CZ304982B6 (cs) * 2012-04-30 2015-03-11 Zentiva, K.S. Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CN102675369B (zh) * 2012-05-16 2017-07-11 北京华众思康医药技术有限公司 一种制备[3‑[(2r)‑[(1r)‑1‑[3，5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4，5‑二氢‑[1，2，4]‑三唑‑1‑基]膦酸一苄酯的新方法
BR112014029131B1 (pt) * 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
HUE051147T2 (hu) 2012-07-06 2021-03-01 Pharmathen Sa Neurokinin-1-receptor antagonista stabil injektálható gyógyszerkészítmény és eljárás annak elõállítására
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
CA2889977A1 (en) * 2012-10-29 2014-05-08 Allergan, Inc. Phosphate esters of bimatoprost and the prostamides
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
ES2493693B1 (es) 2013-02-11 2015-07-07 Servicio Andaluz De Salud Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
WO2014134413A2 (en) * 2013-03-01 2014-09-04 Revlon Consumer Products Corporation Cyrrhetinic alkyl esters and protected derivatives thereof
EP3932932A1 (en) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
JP6356218B2 (ja) * 2013-04-18 2018-07-11 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法
CA2914100A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3062808B1 (en) 2013-10-28 2021-09-29 The Regents of the University of California Treatment of metastatic prostate cancer
CN104650142B (zh) * 2013-11-25 2018-06-22 山东新时代药业有限公司 一种福沙匹坦二甲葡胺的制备方法
CN103694146B (zh) * 2013-12-04 2015-10-28 深圳万乐药业有限公司 2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
US20160324881A1 (en) 2013-12-30 2016-11-10 Oncoprevent Gmbh Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
US9688699B2 (en) 2014-02-19 2017-06-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
JP2017536396A (ja) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロアリール置換イミダゾ［１，２−ａ］ピリジンおよびその使用
CA2991313C (en) 2015-07-06 2023-12-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017021880A1 (en) 2015-08-03 2017-02-09 Leiutis Pharmaceuticals Pvt Ltd Liquid formulations of fosaprepitant
US10005803B2 (en) 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
EP3383829B1 (en) 2015-12-01 2020-10-21 Piramal Enterprises Limited A process for preparation of fosaprepitant dimeglumine and an intermediate thereof
CN105837526B (zh) * 2016-01-22 2018-02-27 浙江工业大学 一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法
AU2017240157B2 (en) 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN107353303B (zh) 2016-05-09 2020-09-01 上海奥博生物医药技术有限公司 一种福沙匹坦磷酸酯中间体的制备方法
MD3435980T2 (ro) 2016-06-06 2020-03-31 Helsinn Healthcare Sa Formulări injectabile de fosnetupitant echilibrate fiziologic
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
AU2017345399B2 (en) 2016-10-18 2022-02-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
NZ752732A (en) 2016-10-18 2024-08-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
BR112019021125A2 (pt) 2017-04-10 2020-05-12 Chase Therapeutics Corporation Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
CN109694390A (zh) * 2017-10-24 2019-04-30 齐鲁制药有限公司 一种福沙匹坦氮氧化物
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
AU2019223237A1 (en) * 2018-02-26 2020-09-03 Ospedale San Raffaele S.R.L. NK-1 antagonists for use in the treatment of ocular pain
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
MX2022011545A (es) 2020-04-03 2022-11-09 Nerre Therapeutics Ltd Un antagonista de receptor de nk-1 para tratar una enfermedad que se selecciona de sepsis, choque septico, síndrome de dificultad respiratoria aguda (ards) 0 síndrome de disfunción orgánica múltiple (mcds).
CN115697332A (zh) 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂
CN116546973A (zh) 2020-11-19 2023-08-04 日本化药株式会社 含有发生血管障碍的水溶性药物的组合物、含有发生血管障碍的水溶性药物的给药液调制用溶液、试剂盒、血管障碍抑制剂和含有非离子型表面活性剂的溶液
EP4052696A1 (en) 2021-03-04 2022-09-07 Extrovis AG Stable ready-to-use parenteral compositions of fosaprepitant
CN113582982B (zh) * 2021-06-15 2023-06-16 山东罗欣药业集团股份有限公司 一种nk1受体拮抗剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA676161A (en) * 1963-12-17 Hoffmann Karl Benzimidazolyl-acetic acid derivatives and process for their manufacture
US2943022A (en) * 1958-02-25 1960-06-28 Ravensberg G M B H Substituted 1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds and process of making same
DE1138057B (de) * 1958-04-03 1962-10-18 Ravensberg G M B H Chem Fab Verfahren zur Herstellung von 1-Phenyl-2, 3-dimethyl-4-morpholino-methyl-pyrazolon-(5)-derivaten
GB852727A (en) * 1959-06-24 1960-11-02 Ravensberg G M B H Analgesic compounds
US3458509A (en) * 1966-10-24 1969-07-29 Dow Chemical Co 4-allyltetrahydro-dimethyl-2h-1,4-thiazines
DE1670840A1 (de) * 1967-03-31 1971-03-11 Bayer Ag Verfahren zur Herstellung von Tetra-hydro-1,4-thiazin-1,1-dioxiden
US3506673A (en) * 1968-03-29 1970-04-14 Aldrich Chem Co Inc 2-(4'halo)-benzhydryl-3-quinuclidinols
GB1452701A (en) * 1974-05-07 1976-10-13 Ici Ltd Morpholine derivatives
IE50355B1 (en) * 1979-10-20 1986-04-02 Wyeth John & Brother Ltd Morpholine derivatives
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
DE3134842A1 (de) * 1981-09-03 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Neue anilino-1,2,3-triazol-derivate, diese enthaltende arzneimittel sowie verfahren zu deren herstellung und deren verwendung
FR2534915B1 (fr) * 1982-10-26 1985-10-25 Lafon Labor Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation
US4435395A (en) * 1983-03-03 1984-03-06 Usv Pharmaceutical Corporation N-Substituted 1,4-dihydropyridazines and pharmaceutical compositions
DE3421810A1 (de) * 1984-06-12 1985-12-12 Basf Ag, 6700 Ludwigshafen Phenylalkylamine - bioregulatoren
FR2612926B1 (fr) * 1987-03-24 1989-06-09 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant
DE3800977A1 (de) * 1988-01-15 1989-07-27 Ant Nachrichtentech Digitalsignal-uebertragungssystem mit linienersatzbetrieb
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
FI892468A (fi) * 1988-05-23 1989-11-24 Glaxo Group Ltd Piperazinderivat.
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DE3901244A1 (de) * 1989-01-18 1990-07-19 Basf Ag Phenylalkylamine und diese enthaltende fungizide
US5070090A (en) * 1989-05-15 1991-12-03 Janssen Pharmaceutica N.V. Antipicorpaviral herterocyclic-substituted morpholinyl alkylphenol ethers
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
HUT62891A (en) * 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
DK178590D0 (da) * 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
HUT68667A (en) * 1990-09-28 1995-07-28 Pfizer Fused ring analogs of nitrogen containing nonaromatic heterocycles
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
AU652407B2 (en) * 1991-01-10 1994-08-25 Pfizer Inc. N-alkyl quinuclidinium salts as substance P antagonists
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
ATE154354T1 (de) * 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
US5459270A (en) * 1991-08-20 1995-10-17 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
EP0916346A3 (en) * 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists

Also Published As

Publication number Publication date
YU14495A (sh) 1999-07-28
PL316143A1 (en) 1996-12-23
HUT76324A (en) 1997-08-28
DE69528823T2 (de) 2003-07-03
DE122008000037I1 (de) 2008-11-06
CA2183250C (en) 2006-03-21
US5691336A (en) 1997-11-25
US5716942A (en) 1998-02-10
MX9603845A (es) 1997-07-31
FR08C0019I2 (fr) 2009-10-30
LV11688B (en) 1997-06-20
WO1995023798A1 (en) 1995-09-08
CN1147254A (zh) 1997-04-09
NO963675D0 (no) 1996-09-03
EP0748320B1 (en) 2002-11-13
ZA951780B (en) 1995-11-15
FI963450A (fi) 1996-09-03
JP3073770B2 (ja) 2000-08-07
NZ282586A (en) 1998-07-28
BG62811B1 (bg) 2000-08-31
US5780467A (en) 1998-07-14
TW385308B (en) 2000-03-21
AU1975095A (en) 1995-09-18
ATE227722T1 (de) 2002-11-15
AU700611B2 (en) 1999-01-07
CZ288241B6 (en) 2001-05-16
HRP950099A2 (en) 1998-04-30
KR977001713A (ko) 1997-04-12
RU2170233C2 (ru) 2001-07-10
ES2184794T3 (es) 2003-04-16
FR08C0019I1 (pt) 2008-07-18
PL180522B1 (pl) 2001-02-28
SK112396A3 (en) 1997-03-05
NO310074B1 (no) 2001-05-14
CO4340689A1 (es) 1996-07-30
LV11688A (lv) 1997-02-20
JPH09509935A (ja) 1997-10-07
IL112778A0 (en) 1995-05-26
FI963450A0 (fi) 1996-09-03
CA2183250A1 (en) 1995-09-08
CN1075812C (zh) 2001-12-05
CZ258896A3 (en) 1997-03-12
US5512570A (en) 1996-04-30
NO963675L (no) 1996-11-04
HU9602409D0 (en) 1996-11-28
EP0748320A1 (en) 1996-12-18
BG100798A (bg) 1997-03-31
DE69528823D1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
BR9507046A (pt) Composto prodroga de um composto originário compusiçao farmacêutica processos para antagonizar o efeito de substância p em seu sitio receptor ou para bloquear receptores de neuroquinina- 1 em um mamifero para tratar ou prevenir dor ou nocicepçao atribuivel a ou associada com enxaqueca uma condiçao selecionada no grupo consistindo de neuropatia diabética periférica relacionada com aids induzida por quimioterapia e neuralgia asma emese e artrite para tratar fibrose cistica e processo para preparar
BR9408351A (pt) Composto composição farmacêutica processos para antagonizar o efeito de substância p e de neuroquinina a no seu sitio receptor processos para tratamento ou prevenção de dor ou nocipecção asma fibrose cistica emese e processo para a preparação de um composto
BR1100375A (pt) Composto, composição farmacêutica, e, processo para a preparação de um composto
NO954400L (no) Substituerte pyrrolidin-3-yl-alkyl-piperidiner som er anvendbare som tachykininantagonister
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
DE69422303D1 (de) Neue 4-piperidinyl substituierte lactame als neukokinin 2 rezeptor antagonisten zur behandlung von asthma
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
ES2132709T3 (es) Nuevas piperidinas substituidas utiles para el tratamiento de las enfermedades alergicas.
ES2135543T3 (es) Piperidinas (4-aril-sustituidas) como antagonistas de los receptores de neuroquininas.
NO20062061L (no) Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
NO982222L (no) 3-(4-Subst.-piperidinyl-1)-1-(3,4-diklorfenyl)propylkarbamater og -ureaer og derivater som neurokinin-antagonister
DE69431069D1 (de) Cyclische amidderivate als neurokinin a antagonisten
NO20052124L (no) Nye 1,4-diazabisykloalkanderivater, deres fremstilling og anvendelse
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
ES2138181T3 (es) Heterociclos biciclicos como antagonistas de la neurokinina.
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
BR0009582A (pt) Composto, composição farmacêutica, e, processopara o tratamento de uma condição de doençaselecionada de artrite reumatóide, doença dealzheimer, câncer, esquizofrenia, edema, rinitealérgica, inflamação, dor, hipermobilidadegastrointestinal , asma gástrica, refluxogastroesfageal, ansiedade, emese, doença dehuntington, psicoses incluindo depressão,hipertensão, enxaqueca e urticária
AU3422800A (en) Use of 5-ht3 receptor antagonists
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
NO983831D0 (no) Nye substituerte N-metyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamider som er anvendbare for behandling av allergiske sykdommer
DK0863873T3 (da) Indolcarbamater som leukotrienantagonister
EA200100361A1 (ru) Сложные эфиры (+)-альфа-(2,3-диметоксифенил)-1-[2-(4-фторфенил)этил]-4-пиперидинметанола и их использование в качестве пролекарств антагониста mdl 110907 5htрецепторов
YU24501A (sh) Estri od(+)-alfa-(2,3-dimetoksifenil)-1-(2-(4-fluorofenil) etil)-4-piperidinmetanola i njihovo korišćenje kao prolekova od 5ht2a receptor antagonista mdl 110,907

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law